Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign - Wikidata - wikimedia - TriplyDB

Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign

Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign

http://www.wikidata.org/entity/Q27681806

about

Harnessing the protective potential of HIV-1 neutralizing antibodies Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.HIV-1 Env-specific memory and germinal center B cells in C57BL/6 mice Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.Identification of novel viral receptors with cell line expressing viral receptor-binding protein.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.Phenotypic Correlates of HIV-1 Macrophage Tropism.Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence.High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates.Native-like Env trimers as a platform for HIV-1 vaccine design.Insights into the trimeric HIV-1 envelope glycoprotein structure HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Evolution of B cell analysis and Env trimer redesign.The ClusPro web server for protein-protein docking.Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.The HIV-1 envelope glycoprotein structure: nailing down a moving target.Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.HIV-1 Cross-reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Non-human Primate.

P2860

Q26766153-B49655A4-4865-464C-9F36-FA69EA4AFA23 Q27319450-2466C76F-96E5-437C-9D4B-AB19EBD7E72D Q27322403-3C579E27-BA1F-4080-94CE-65F3317857D1 Q27324184-860A5AEB-0E4A-4700-A1B7-A98685B8A389 Q28263063-DC565F61-1073-4FD9-ADE4-DFCB17EFB4CE Q28553360-68FCBF21-9EC9-4E94-8429-9789AFFE28C7 Q28647225-9D531A38-1C72-44D4-8EE2-2743309E81AD Q33753573-ED864028-CF02-4BA5-AD7C-FB0A21B7A7F7 Q34303547-E4861AB6-9FD5-4781-BA78-1C44E0EC5E5D Q34594905-7FF46280-775C-4854-80BB-472F94DBCCED Q34709433-24515420-7369-4E5D-8EEE-8C2E96AF8FE4 Q34990603-E9760694-7C6B-429F-BD30-65C2EBEFC209 Q35110976-02554C07-1D0E-410C-B3EC-9166F3A267D2 Q35169535-96F9CF30-65D2-43A3-85C0-E0152556DED0 Q35540033-D934A22F-9EC8-4D3C-83A9-94C26A55E17F Q35691113-D188E666-DE17-4AF2-B0EB-C8C3CAEC38C5 Q35925858-6E535BE4-7D49-436E-A4AC-B8929C8FA715 Q35985519-3730DFE2-4799-4D30-9F64-4BC0E414B4BF Q36086357-19772F19-7C4C-42D9-A8D2-8381A72844F2 Q36245216-AB855555-A168-4CCA-91D3-277AD56486ED Q36281817-00DC2E82-DB57-47EC-A051-61EC9D143B42 Q36290038-2A71F501-7A42-4029-8FE4-FF0034E5F8B5 Q36303368-4EA09990-8FA1-45C2-B256-48FF8319A405 Q36334312-F99EBB67-2B60-40CA-8941-48604A10D399 Q36434196-2F47B98A-AB4D-492A-81BE-712DB1EAEEFA Q36583109-26602209-BB2E-4F0D-9C6C-EEAE8C4938A1 Q36627503-5AB00195-B2E6-4019-B21B-0D778986F96D Q36905471-7D6AB5F3-D88E-4F1B-B861-644C2F1AAD4B Q36957800-4A661C88-7BF7-4B5F-BEE9-0F55ABA53392 Q37300461-A93807CB-DA6F-41BE-90F3-4FB35D38B1B4 Q37633417-0A7435F5-FEEF-4169-B947-1E6A11EDCE77 Q38323609-30316AC7-C873-4FE1-80B6-5DA45A476C41 Q38665463-8295B229-2598-4C78-AAE4-648BC0CF2230 Q38992740-C260AB74-A9CA-486A-AC52-75DCDCC073E5 Q39024817-382C2DA5-DD23-4AA8-95BF-D706278F1BEF Q39108730-D1E4DFDD-3339-4B65-B0F7-6E9FFB77CB1D Q39108789-8A031B82-1948-4257-8D75-485E13043980 Q40043429-CB0BE8C2-D894-4950-BC90-64568EFD21DD Q40056179-8CED7C9B-D249-4A0F-B1DB-C9B23A4A049F Q40073016-82BF3F7B-036F-4A9F-A3C6-010C7C4B7478

P2860

Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign

http://www.wikidata.org/entity/Q27681806

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@ast

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@en

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@nl

type

label

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@ast

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@en

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@nl

prefLabel

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@ast

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@en

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@nl

P1433

Q27681806-165EB44D-0335-4854-A468-91255A87E8A6

P1476

Q27681806-B17FE3F1-0BC5-413D-B587-F0F360EEED86

P2093

Q27681806-1F8308A8-6F9E-4B8A-8F34-DAE22663AA78

Q27681806-550B88A6-415B-47B4-B2F1-78E1D47E4A24

Q27681806-908E9EE3-93E6-4E54-BCE8-A948C6FB345C

Q27681806-91B8EF8A-943F-4395-AEF6-9F4C08FB2407

Q27681806-9A9C73AF-E886-432F-95F6-F45DE6389F0F

Q27681806-AB13FE51-FDA0-4DBB-9E45-6DBE73FFBB18

Q27681806-B3089311-6365-4E6B-8DCC-56C5C381802F

Q27681806-B8D5D2A8-1666-496E-B4ED-1261A2F26769

Q27681806-BB1FBE9A-CBA4-4092-8768-0428CFC899E1

Q27681806-BB4E54EE-3441-4F4A-9CE9-6F570FBCC91B

P2860

Q27681806-0241ADC3-23DC-4F51-9F17-737EB848937F

Q27681806-05015F2C-F1A5-4B9C-84DD-3684C407D3CB

Q27681806-07D20D6E-ED8A-4473-A9D0-A8D18953A7BB

Q27681806-0803F0C8-2C19-4815-B95B-185FEB522B82

Q27681806-14D8071A-E5EA-425C-B8E1-90C66EE94ADA

Q27681806-171398D7-2252-4603-9854-4CB64C4DD700

Q27681806-1CC9D712-6FA4-4C20-8333-C68C2D136CC3

Q27681806-1F809EBB-9136-4A62-A13B-23D26758003F

Q27681806-2C933E57-B819-45D8-A724-9A81831FB947

Q27681806-2CCBAED8-F71F-456B-83F7-0CF4708C9B65

P304

Q27681806-CA3CCDEE-841F-4822-A7F5-FE5AA966B814

P31

Q27681806-A867A61B-AC84-4734-AB42-AD605D569895

P3181

Q27681806-942ADFA8-8A8E-439E-A946-124735D7C263

P356

Q27681806-13E7DC98-06E4-4567-933D-5CBE93524832

P407

Q27681806-176D0087-4127-4F00-9FFF-2EE5849B3F20

P433

Q27681806-6C5487F0-9655-461A-A41A-30FB82A80810

P478

Q27681806-AE433C90-BC1A-4AA1-A884-E9B0C01DCBF8

P50

Q27681806-18F32405-E848-48A2-95BC-191730711214

Q27681806-F78D38C2-D7AE-4AB8-BD48-A31C93DD6FE5

P577

Q27681806-44F3347B-5938-4A9E-8E7F-5E8A97226AA5

P698

Q27681806-CFAFC62B-3011-4D8A-8CB2-F5CEB8FAC190

P921

Q27681806-968CB424-A144-48EC-9FED-811B15830222

P932

Q27681806-505A73F5-95FC-4D4D-BB47-23E8DE2DFAEF

P3181

P356

PNAS.1319512111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Vaccine-elicited primate antib ...... ite informing vaccine redesign

@en

P2093

Andrew B Ward

http://www.w3.org/2001/XMLSchema#string

Christian Poulsen

http://www.w3.org/2001/XMLSchema#string

Gunilla B Karlsson Hedestam

http://www.w3.org/2001/XMLSchema#string

Javier Guenaga

http://www.w3.org/2001/XMLSchema#string

Karen Tran

http://www.w3.org/2001/XMLSchema#string

Natalia de Val Alda

http://www.w3.org/2001/XMLSchema#string

Natalia de Val

http://www.w3.org/2001/XMLSchema#string

Richard T Wyatt

http://www.w3.org/2001/XMLSchema#string

Richard Wilson

http://www.w3.org/2001/XMLSchema#string

Robyn L Stanfield

http://www.w3.org/2001/XMLSchema#string

P2860

Structural mechanism of trimeric HIV-1 envelope glycoprotein activation

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

MolProbity: all-atom structure validation for macromolecular crystallography

Structural definition of a conserved neutralization epitope on HIV-1 gp120

A Blueprint for HIV Vaccine Discovery

HIV-1 neutralizing antibodies: understanding nature's pathways

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

P304

E738-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2384020

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1319512111

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Christopher Sundling

Ian Andrew Wilson

P577

2014-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24550318

http://www.w3.org/2001/XMLSchema#string

P921

P932

3932900

http://www.w3.org/2001/XMLSchema#string